

Executive Summary for SAGE Human papilloma virus (HPV) vaccines- Session 7- Wednesday, 24 October 2018

Background:

A SAGE working group was established in June 2018 to evaluate the potential contribution of HPV vaccines and immunization towards cervical cancer elimination. The working group will develop and propose interim goals that can be achieved through immunization as part of the efforts towards cancer elimination as well as to propose indicators to monitor the accomplishment of these interim goals.

Session Objective:

Present SAGE with updated evidence on HPV-related burden, HPV vaccines, impact of HPV immunization programmes, and modelling of impact of HPV immunization schedules and strategies.

SAGE is requested to consider the following questions:

1. What are the potential effect and cost effectiveness of various vaccination strategies towards the achievement of cervical cancer elimination?
2. What is the potential contribution of HPV vaccination towards cervical cancer elimination?
3. What are the interim goals that can be achieved through immunization as part of the efforts towards cancer elimination.
4. What are the indicators to monitor the accomplishment of these interim goals?
5. What is the additional research related to vaccines and immunization needed to attain these goals and outline potential innovations that may help enhance the achievement of these goals?

Session Summary:

1. Presentation: update on HPV vaccine introduction and programmatic perspective.
2. Presentation: an overview of HPV burden of disease and effects of HPV immunization strategies.
3. Presentation: review of the evidence regarding HPV immunization on different disease outcomes.
4. Presentation: compare the impact of different immunization strategies and scenarios towards cervical cancer elimination.

Background Reading (Web):

- 1- IVIR-AC recommendation 24-25th September meeting
- 2- SAGE WG meeting report 27-28th September meeting
- 3- HPV Background document
- 4- Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Siok Shen Ng a,b, Raymond Hutubessy c, Nathorn Chaiyakunapruk; Vaccine 2018.

- 5- Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. Siobhan Botwright, Taylor Holroyd, Shreya Nanda, Paul Bloem, Ulla K. Griffiths⁴, Anissa Sidibe, Raymond C. W. Hutubessy. PLoS one 2017.
- 6- Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI. Policy on Introduction Grant Support to Countries. Ann Levin, Susan A. Wang, Carol Levin, Vivien Tsu, Raymond Hutubessy. PLoS one 2014.
- 7- Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. Wilm Quentin, Fern Terris-Prestholt, John Chagalucha, Selephina Soteli, W John Edmunds, Raymond Hutubessy, David A Ross, Saidi Kapiga, Richard Hayes and Deborah Watson-Jones. BMC Medicine 2012.
- 8- A case study using the United Republic of Tanzania: costing nationwide HPV vaccine, delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. Raymond Hutubessy, Ann Levin, Susan Wang, Winthrop Morgan, Mariam Ally, Theopista John and Nathalie Broutet. BMC Medicine 2012.
- 9- HPV vaccines in females over 25. Cochrane
- 10- Worldwide burden of cancer attributable to HPV by site, country and HPV type. Catherine de Martel, Martyn Plummer, Jerome Vignat and Silvia Franceschi. International Journal of Cancer, 2017.
- 11- HPV Vaccine - Global Market Study. Annecy, September 2018 – Tania Cernuschi